
Send a message.
We’re here to answer any question you may have.
careers
Would you like to join our growing team?
careers@hub.com
careers
Would you like to join our growing team?
careers@hub.com
We’re here to answer any question you may have.
Would you like to join our growing team?
careers@hub.com
Would you like to join our growing team?
careers@hub.com
Join us on our mission to accelerate groundbreaking research, drive innovation, and fund transformative treatments for HMERF muscular dystrophy.
We are the only organization in the world funding and advancing research into the ultra-rare HMERF muscular dystrophy so we can develop a life-saving treatment to ensure that no one faces HMERF without hope.
By uniting scientists and healthcare professionals around the world, we are accelerating the advancement of pioneering medical breakthroughs that will lead to therapeutic treatments that will help thousands of lives.
Make a difference in the lives of those battling a rare disease.
Join us in providing hope and support for those who need it most
A life-saving answer to HMERF is within our reach, and we are making great strides. Because of you, we can make a difference and continue our relentless pursuit of developing a therapeutic for HMERF.
For HMERF the genetic defect is located on titin protein chain at exon 344. These mutations can disrupt the normal folding and function of the titin protein , leading to muscle damage and respiratory issues.
Researchers study the target protein to understand its functionality and then synthesize potential drug molecules that might interact with the target protein. Thousands of compounds are analyzed, seeking ones with therapeutic value..
This stage can take up to 6–7 years as researchers synthesize and purify the drug, conduct limited animal testing, and evaluate the therapy in lab (in vitro) and animal (in vivo) models for safety, efficacy, and how it’s processed in the body.
This phase tests the drug in humans across three stages. Phase 1 focuses on safety and metabolism in healthy volunteers. Phase 2 assesses safety, effectiveness, and dosage in patients with the target condition. Phase 3 is the largest and costliest, confirming safety and effectiveness in a broader group. Afterward, researchers file a New Drug Application (NDA) with the FDA for review and expert advisory input.
Using the groundwork of the previous phases, the researchers work toward approval and commercial production of the target treatment that paves the way to changing the lives of these rare disease patients.
HMERF is a rare genetic muscle disorder that primarily affects skeletal muscles and respiratory function. It is caused by mutations in the TTN (titin) gene which plays a crucial role in muscle structure and elasticity.
This type of muscular dystrophy causes a progressive loss of muscle mass, eventually leaving patients to become bedridden and in severe pain. Ultimately, the disease will determine how long each patient can continue to breathe on their own. For each patient, and for unknown reasons, the path through this disease can be very different.
Many people confuse muscular dystrophy (MD) with multiple sclerosis (MS). A simple way to remember the difference is that MD stands for “Muscle Death.” Once muscles die, they cannot regenerate—at least not yet—which makes every moment crucial.
People with HMERF live their lives on a ticking clock, but with your help and support, we can push the science forward and fight back against this devastating disease.
Casey’s story is much like other people with HMERF. A disease that will take her life because the muscles in her body are dying.
A nurse in an outpatient clinic at WellStar Pulmonary Medicine in Georgia, USA, Casey married her high school sweetheart, Josh, and together they have two sons, Joshua and Ethan.
In 2017, Casey was diagnosed with HMERF, and their lives changed forever.
We are proud to bring together leading medical science experts from around the world to lead our efforts in developing a therapeutic cure for HMERF.
Dr. Savarese is the top HMERF geneticist who works with the leading global HMERF researcher, Dr. Udd, overseeing three ongoing studies in Finland, France, and Israel.
Dr. Lindquist research focuses on congenital myopathies such as nemaline myopathies and titinopathies such as HMERF.
Dr Pfeffer’s research focuses on creating a methodology to repair the damaged gene.
Dr Cagnin is an experienced PHD skilled in Sequence Analysis, DNA Sequencing, Bioinformatics, Real-Time Polymerase Chain Reaction (qPCR), and Systems Biology.
Dr Sales is a computational biologist interested in developing highly efficient methods for analyzing large datasets generated by high‑throughput experimental techniques.
Dr Novak brings strong expertise in developing specific therapeutics for other types of muscular dystrophy and is providing invaluable advice as we move toward developing a therapeutic for Casey and other HMERF patients.
Read our progress updates as we get closer to fullfilling our mission.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam at turpis dictum, semper odio a, ullamcorper nisi. Vestibulum arcu tellus, ullamcorper sit amet ex eu, blandit egestas nisi. Nunc pulvinar eget lacus id fermentum. Aenean nec scelerisque erat. Maecenas purus eros, varius a fringilla et, cursus rhoncus justo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam at turpis dictum, semper odio a, ullamcorper nisi. Vestibulum arcu tellus, ullamcorper sit amet ex eu, blandit egestas nisi. Nunc pulvinar eget lacus id fermentum. Aenean nec scelerisque erat. Maecenas purus eros, varius a fringilla et, cursus rhoncus justo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam at turpis dictum, semper odio a, ullamcorper nisi. Vestibulum arcu tellus, ullamcorper sit amet ex eu, blandit egestas nisi. Nunc pulvinar eget lacus id fermentum. Aenean nec scelerisque erat. Maecenas purus eros, varius a fringilla et, cursus rhoncus justo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam at turpis dictum, semper odio a, ullamcorper nisi. Vestibulum arcu tellus, ullamcorper sit amet ex eu, blandit egestas nisi. Nunc pulvinar eget lacus id fermentum. Aenean nec scelerisque erat. Maecenas purus eros, varius a fringilla et, cursus rhoncus justo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam at turpis dictum, semper odio a, ullamcorper nisi. Vestibulum arcu tellus, ullamcorper sit amet ex eu, blandit egestas nisi. Nunc pulvinar eget lacus id fermentum. Aenean nec scelerisque erat. Maecenas purus eros, varius a fringilla et, cursus rhoncus justo.
Adding {{itemName}} to cart
Added {{itemName}} to cart